Onset of action of formoterol versus salmeterol  by Aalbers, René & van der Woude, Hanneke J.
ARTICLE IN PRESS
Respiratory Medicine (2007) 101, 871–8720954-6111/$ - see fro
doi:10.1016/j.rmed.LETTER TO THE EDITOROnset of action of formoterol versus salmeterol
We read with interest the article by Lemaigre et al.,
published in the February 2006 edition of Respiratory
Medicine, which reported no significant difference in the
speed of recovery of pulmonary function following histamine
challenge in patients with asthma treated with either
salmeterol or formoterol.1 We note that this finding opposes
current evidence in this area, which has demonstrated a
significantly faster onset of action for formoterol compared
with salmeterol.2–4 While the study by Lemaigre et al. sets
out to address an important aspect of asthma management,
namely the clinical efficacy of long-acting bronchodilators
on asthma symptoms and bronchoconstriction following
histamine provocation, we believe that the study has some
weaknesses that may limit interpretation of the results.
Lemaigre et al. performed a three-arm, parallel-group
study comparing clinically relevant doses of formoterol and
salmeterol with placebo. We believe that this parallel-group
design may not have been the most suitable choice for a
study of this nature because of the potential for between-
patient variability. A crossover design may have been more
appropriate, especially given the significant between-group
differences in Borg Dyspnoea Scale scores (implying that
patients in each treatment group had a different perception
of dyspnoea) and forced expiratory volume in 1 s (FEV1) at
baseline and the limited number of patients (10) in each
treatment arm.
We also note the high level of spontaneous recovery of
pulmonary function in all three treatment arms, as shown by
a drop in FEV1 of 10% predicted normal at 5min post dose in
the placebo group. Spontaneous recovery from bronchocon-
striction as the spasmogenic effect of the mediator subsides
is a bias that affects all bronchial challenge models.
Histamine has been shown to have the most transient
bronchoconstrictor effect of all commonly used asthma
triggers (including methacholine and adenosine 50-monopho-
sphate) and, as such, any study employing histamine as the
challenging mediator will be particularly susceptible to this
bias. Given the methodology used, assessment of the
effect of the study drugs at 1 and 3min post-dose may
have facilitated discrimination between the two active
treatments.
In addition, we suggest that it may have been more
appropriate when using histamine to have aimed for a 30%
fall in FEV1 following challenge (rather than a 20% fall) to
compensate for the rapid spontaneous recovery seen withnt matter & 2006 Published by Elsevier Ltd.
2006.06.023this mediator. Previous work in this area has shown that a
10% fall in FEV1 represents the lower limit for detecting a
difference in Borg score when using methacholine as the
mediator.5 If this 10% limit is considered, the 5-min
measurement appears to be the only valid assessment in
the study by Lemaigre et al. At this timepoint, the change
in FEV1 was 10% predicted normal in the placebo group, 12%
predicted normal in the salmeterol group and 16% pre-
dicted normal in the formoterol group, suggesting superior
efficacy with formoterol treatment during the first 5min
post dose.
To further aid interpretation of the data, it would have
been beneficial to know the degree of bronchoconstriction
immediately following histamine challenge (i.e. at t ¼ 0)
and to have some indication of the variability in the
observations (such as the standard deviation, standard error
of the mean or confidence intervals). It would have also
been helpful to have had details of the power analysis,
which would have enabled evaluation of the strength of the
statistical analysis.
Finally, use of the Asthma Symptom Checklist (ASC)
questionnaire to assess bronchodilatory efficacy is uncom-
mon and has not been sufficiently documented to be relied
upon as a clinical tool. In the study by Lemaigre et al. there
is an apparent correlation between the FEV1 measurements
and ASC score that may validate its use in this specific
setting, but given the limitations in the overall study design,
we suggest that this correlation should be interpreted with
care.
As already mentioned, current evidence indicates that
formoterol has a faster onset of action than salmeterol.2–4
However, the results presented by Lemaigre et al. are in
conflict with this evidence. We suggest that the limitations
of the study design and methodology used by Lemaigre et al.
should be considered when interpreting the data and we
urge colleagues to exercise a degree of caution when
applying these results in clinical practice.References
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